GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lincoln Pharmaceuticals Ltd (BOM:531633) » Definitions » Cyclically Adjusted Revenue per Share

Lincoln Pharmaceuticals (BOM:531633) Cyclically Adjusted Revenue per Share : ₹282.67 (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Lincoln Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Lincoln Pharmaceuticals's adjusted revenue per share for the three months ended in Sep. 2024 was ₹80.514. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹282.67 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Lincoln Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 6.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Lincoln Pharmaceuticals was 6.70% per year. The lowest was 6.70% per year. And the median was 6.70% per year.

As of today (2025-01-18), Lincoln Pharmaceuticals's current stock price is ₹806.30. Lincoln Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was ₹282.67. Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 2.85.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lincoln Pharmaceuticals was 3.28. The lowest was 0.96. And the median was 1.50.


Lincoln Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Lincoln Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lincoln Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Lincoln Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 222.80 235.25 253.40 271.01

Lincoln Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 266.47 270.98 271.01 278.47 282.67

Competitive Comparison of Lincoln Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Lincoln Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lincoln Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=80.514/157.8822*157.8822
=80.514

Current CPI (Sep. 2024) = 157.8822.

Lincoln Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 39.612 96.780 64.621
201503 48.329 97.163 78.531
201506 44.912 99.841 71.021
201509 58.504 101.753 90.776
201512 65.012 102.901 99.749
201603 71.676 102.518 110.384
201606 54.728 105.961 81.545
201609 45.557 105.961 67.880
201612 35.137 105.196 52.735
201703 61.986 105.196 93.031
201706 74.924 107.109 110.441
201709 44.814 109.021 64.899
201712 40.102 109.404 57.872
201803 33.611 109.786 48.335
201806 49.886 111.317 70.754
201809 51.302 115.142 70.345
201812 42.186 115.142 57.845
201903 34.990 118.202 46.736
201906 48.370 120.880 63.176
201909 56.361 123.175 72.242
201912 49.304 126.235 61.664
202003 34.396 124.705 43.547
202006 51.905 127.000 64.526
202009 63.057 130.118 76.512
202012 57.282 130.889 69.095
202103 35.014 131.771 41.952
202106 61.015 134.084 71.844
202109 63.661 135.847 73.987
202112 59.865 138.161 68.410
202203 49.269 138.822 56.034
202206 61.606 142.347 68.329
202209 70.208 144.661 76.625
202212 66.783 145.763 72.336
202303 53.494 146.865 57.507
202306 67.691 150.280 71.115
202309 77.897 151.492 81.183
202312 73.119 152.924 75.490
202403 66.474 153.035 68.580
202406 73.542 155.789 74.530
202409 80.514 157.882 80.514

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Lincoln Pharmaceuticals  (BOM:531633) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=806.30/282.67
=2.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lincoln Pharmaceuticals was 3.28. The lowest was 0.96. And the median was 1.50.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Lincoln Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Lincoln Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lincoln Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Science City Road, Lincoln House, Behind Satyam Complex, Sola, Ahmedabad, GJ, IND, 380060
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.

Lincoln Pharmaceuticals Headlines

No Headlines